Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 3/20 | 0.47 |
| ▸ | GABRD | O14764 | 3/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.47 |
| ▸ | GABRE | P78334 | 3/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30028472 | 0.83 | PARP1 (0.57) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL13462372 | 0.82 | SMN1; SMN2 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1997423 | 0.81 | SMN1; SMN2 (0.57) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL24834805 | 0.81 | GABRP (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7330187 | 0.81 | GABRP (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL920438 | 0.80 | S1PR4 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL12590479 | 0.80 | MAPT (0.44) | SMN1; SMN2LMNAPARP1RAB9AALDH1A1 | |
| SCHEMBL12908111 | 0.79 | SMN1; SMN2 (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6051830 | 0.79 | GABRP (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10718195 | 0.79 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200223837-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2020-07-16 | — | — | US | disclosed |
| EP-3638662-A1 | BENZOFURAN UREAS OR CARBAMATES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | European Molecular Biology Laboratory (DE) | 2020-04-22 | — | — | EP | disclosed |
| EP-3638664-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | European Molecular Biology Laboratory (DE) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018229193-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2018-12-20 | — | — | WO | disclosed |
| WO-2018229194-A1 | BENZOFURAN UREAS OR CARBAMATES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2018-12-20 | — | — | WO | disclosed |
| EP-2903965-B1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | ORION CORP (FI) | 2017-03-01 | — | — | EP | disclosed |
| US-9567325-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-02-14 | — | — | US | disclosed |
| US-9533952-B2 | N-prop-2-ynyl carboxamide derivatives and their use as TRPA1 antagonists | ORION CORPORATION (FI) | 2017-01-03 | — | — | US | disclosed |
| US-20150376130-A1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | Orlon Corporation (FI) | 2015-12-31 | — | — | US | disclosed |
| EP-2903965-A1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | Orion Corporation (FI) | 2015-08-12 | — | — | EP | disclosed |
| US-6344463-B1 | SKIN DISORDERS, ACNE | ALLERGAN SALES, INC. | 2002-02-05 | — | — | US | disclosed |
| EP-0636127-B1 | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity | ALLERGAN INC (US) | 2001-04-04 | — | — | EP | disclosed |
| US-6090826-A | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity | ALLERGAN SALES, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-5750693-A | THIOCHROMANYL OR CHROMANYL COMPOUNDS AS ANTICARCINOGINIC AGENTS, SKIN DISORDERS AND ATHEROSCLEROSIS | ALLERGAN (US) | 1998-05-12 | — | — | US | disclosed |
| US-5663347-A | REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION; TREATMENT OF SKIN DISORDERS; ANTICARCINOGNIC AGENTS | ALLERGAN (US) | 1997-09-02 | — | — | US | disclosed |
| US-5659042-A | Method for preparing esters of halonicotinic acids | ALLERGAN (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0788482-A1 | METHOD FOR PREPARING ESTERS OF HALONICOTINIC ACIDS | Allergan (US) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996012701-A1 | METHOD FOR PREPARING ESTERS OF HALONICOTINIC ACIDS | ALLERGAN (US) | 1996-05-02 | — | — | WO | disclosed |
| US-5468879-A | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity | ALLERGAN, INC. (US) | 1995-11-21 | — | — | US | disclosed |
| US-5264578-A | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity | ALLERGAN, INC. (US) | 1993-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376130-A1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | GABRP 355/4885GABRD 913/4885GABRA1 385/4885 |
| US-20200223837-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | SUCNR1, CBR1, CYP2A13 | GABRP 2062/4885GABRD 1836/4885GABRA1 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.